Browsing Category
Pharma Industry News
4720 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Could Biogen and UCB finally crack one of biotech’s toughest lupus markets?
Biogen and UCB have a lupus win, but one more Phase 3 test decides the story. See why dapirolizumab pegol matters now.
Whitehawk Therapeutics (Nasdaq: WHWK) stock focus sharpens as ASCO 2026 data support SEZ6 ADC strategy in small cell lung cancer
Find out how Whitehawk Therapeutics’ SEZ6 data at ASCO 2026 could shape its HWK-206 ADC strategy in small cell lung cancer.
Can Kelun-Biotech and Merck turn sac-TMT into the first ADC plus immunotherapy standard in front-line lung cancer?
Merck needs life after Keytruda. Kelun-Biotech’s sac-TMT lung cancer data may show how the next oncology cycle takes shape.
Dizal Pharmaceutical deepens NSCLC pipeline case as DZD6008 and golidocitinib data sharpen ASCO 2026 focus
Read how Dizal’s ASCO 2026 NSCLC data for DZD6008 and golidocitinib could reshape its lung cancer pipeline strategy today!
Amplia Therapeutics (ASX: ATX) stock faces its next big test as narmafotinib moves deeper into cancer trials
Find out how Amplia Therapeutics’ FY2026 report frames ASX: ATX, narmafotinib trials, cash runway and investor sentiment today!
Replimune (REPL) soars 86% as WSJ says White House intervention reopens RP1 review
Replimune jumped nearly 86% after the WSJ reported White House officials pushed the FDA to reconsider twice-rejected RP1. A reopened path, and a binary bet on approval.
Panacea Biotec (NSE: PANACEABIO) names Rajinder Singh Manku to board while consolidated revenue rises in FY26
Find out how Panacea Biotec’s board change, FY26 loss and no-dividend call could shape investor sentiment after its latest results.
Why NCEL-101’s FDA pathway could influence the future of stem-cell-derived islet therapies
Why NewcelX Ltd.’s FDA pre-IND process for NCEL-101 could shape the future of regenerative diabetes medicine. Read the full analysis.
How the NOPAIN Act could support broader reimbursement momentum for EXPAREL
Could the NOPAIN Act accelerate EXPAREL adoption in outpatient orthopedic surgery? Explore the reimbursement and opioid-reduction implications.
Bristol Myers Squibb myeloma drug doubles progression-free survival in pivotal SUCCESSOR-2 trial
Bristol Myers Squibb's mezigdomide doubled myeloma progression-free survival to 18 months and cut progression or death risk 52% in Phase 3, key to its patent-cliff plan.